Evidence map›Paper›PMID 31628465›Full record

Trial reportThe Journal of clinical endocrinology and metabolism2020

Effects of Peptide YY on the Hypothalamic-Pituitary-Gonadal Axis in Healthy Men.

Chioma Izzi-Engbeaya, Sophie Jones, Yoshibye Crustna, Pratibha C Machenahalli, Deborah Papadopoulou, Manish Modi, Christos Panayi, Jessica Starikova, Pei Chia Eng, Maria Phylactou and 16 more

Open access · hybridAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The Journal of clinical endocrinology and metabolism, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 7 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 3 institutions in 2 countries.

Chioma Izzi-EngbeayaSection of Endocrinology and Investigative Medicine, Department of Medicine, Imperial College London, London, UK.
Sophie JonesSection of Endocrinology and Investigative Medicine, Department of Medicine, Imperial College London, London, UK.
Yoshibye CrustnaSection of Endocrinology and Investigative Medicine, Department of Medicine, Imperial College London, London, UK.
Pratibha C MachenahalliSection of Endocrinology and Investigative Medicine, Department of Medicine, Imperial College London, London, UK.
Deborah PapadopoulouSection of Endocrinology and Investigative Medicine, Department of Medicine, Imperial College London, London, UK.
Manish ModiSection of Endocrinology and Investigative Medicine, Department of Medicine, Imperial College London, London, UK.
Christos PanayiSection of Endocrinology and Investigative Medicine, Department of Medicine, Imperial College London, London, UK.
Jessica StarikovaSection of Endocrinology and Investigative Medicine, Department of Medicine, Imperial College London, London, UK.
Pei Chia EngSection of Endocrinology and Investigative Medicine, Department of Medicine, Imperial College London, London, UK.
Maria PhylactouSection of Endocrinology and Investigative Medicine, Department of Medicine, Imperial College London, London, UK.
Edouard MillsSection of Endocrinology and Investigative Medicine, Department of Medicine, Imperial College London, London, UK.
Lisa YangSection of Endocrinology and Investigative Medicine, Department of Medicine, Imperial College London, London, UK.
Risheka RatnasabapathySection of Endocrinology and Investigative Medicine, Department of Medicine, Imperial College London, London, UK.
Mark SykesSection of Endocrinology and Investigative Medicine, Department of Medicine, Imperial College London, London, UK.
Isabella PlumptreSection of Endocrinology and Investigative Medicine, Department of Medicine, Imperial College London, London, UK.
Ben CoumbeSection of Endocrinology and Investigative Medicine, Department of Medicine, Imperial College London, London, UK.
Victoria WingSection of Endocrinology and Investigative Medicine, Department of Medicine, Imperial College London, London, UK.
Ewa PacuszkaSection of Endocrinology and Investigative Medicine, Department of Medicine, Imperial College London, London, UK.
Paul BechSection of Endocrinology and Investigative Medicine, Department of Medicine, Imperial College London, London, UK.
James MinnionSection of Endocrinology and Investigative Medicine, Department of Medicine, Imperial College London, London, UK.
George TharakanSection of Endocrinology and Investigative Medicine, Department of Medicine, Imperial College London, London, UK.
Tricia TanSection of Endocrinology and Investigative Medicine, Department of Medicine, Imperial College London, London, UK.
Johannes VeldhuisDepartment of Internal Medicine, Mayo Clinic, Minnesota.
Ali AbbaraSection of Endocrinology and Investigative Medicine, Department of Medicine, Imperial College London, London, UK.
Alexander N ComninosSection of Endocrinology and Investigative Medicine, Department of Medicine, Imperial College London, London, UK.
Waljit S DhilloSection of Endocrinology and Investigative Medicine, Department of Medicine, Imperial College London, London, UK.
Imperial College London · GBImperial College Healthcare NHS Trust · GBWinnMed · US

Funding

Biotechnology and Biological Sciences Research CouncilDepartment of Health CS-2018-18-ST2-002Department of Health RP-2014-05-001Medical Research Council MR/M004171/1Medical Research Council MR/N020472/1Medical Research Council MR/R000484/1Medical Research Council MR/T006242/1Wellcome Trust
6 · The paper itself

Abstract

contextCentral and peripheral administration of peptide YY (PYY) has potent anorectic effects, and PYY analogs are under development as antiobesity treatments. Recent animal data suggest PYY may also influence the reproductive axis; however the effects of PYY on the human reproductive system are unknown.

objectiveTo investigate the effects of PYY administration on the reproductive axis in healthy young men.

designSingle-blind, randomized, placebo-controlled crossover study.

settingClinical Research Facility, Imperial College Healthcare NHS Trust.

participantsEighteen healthy eugonadal men (mean age 24.1 ± 0.9 years, mean body mass index 22.2 ± 0.4 kg/m2).

interventionEight-hour intravenous infusion of 0.4 pmol/kg/min PYY3-36 or rate-matched vehicle infusion.

main outcome measuresNumber of luteinizing hormone (LH) pulses, LH, follicle stimulating hormone (FSH), and testosterone levels.

resultsThe number of LH pulses (mean number of LH pulses/8 hours: PYY 4.4 ± 0.3 vs vehicle 4.4 ± 0.4, P > .99), LH area under the curve (AUC) (PYY 1503 ± 79 IU.min/L vs vehicle 1574 ± 86 IU.min/L, P = .36), FSH AUC (PYY 1158 ± 513 IU.min/L vs vehicle 1199 ± 476 IU.min/L, P = .49) and testosterone AUC (PYY 10 485 ± 684 IU.min/L vs vehicle 11 133 ± 803 IU.min/L, P = .24) were similar during PYY and vehicle infusions.

conclusionsAcute intravenous infusion of 0.4 pmol/kg/min PYY does not affect the reproductive axis in healthy men.

Indexed as

AdolescentAdultBiomarkersCross-Over StudiesFollicle Stimulating HormoneFollow-Up StudiesHealthy VolunteersHumansHypothalamo-Hypophyseal SystemLuteinizing HormoneMalePeptide YYPrognosisSingle-Blind MethodTestosteroneYoung AdultBiomarkersFollicle Stimulating HormoneLuteinizing HormonePeptide YYTestosterone

Identifiers

PMID31628465
PMCPMC7093052
OpenAlexW2980461954

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.